{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:47:29Z","timestamp":1785322049959,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41397-019-0110-4","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T14:57:51Z","timestamp":1571324271000},"page":"227-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Dissecting the m6A methylation affection on afatinib resistance in non-small cell lung cancer"],"prefix":"10.1038","volume":"20","author":[{"given":"Qianqian","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"key":"110_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"110_CR2","first-page":"149","volume":"4","author":"P Chunhacha","year":"2012","unstructured":"Chunhacha P, Chanvorachote P. Roles of caveolin-1 on anoikis resistance in non small cell lung cancer. Int J Physiol Pathophysiol Pharmacol. 2012;4:149\u201355.","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"110_CR3","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJMra0802714","volume":"359","author":"RS Herbst","year":"2008","unstructured":"Herbst RS, Heymach JV, Lippman SM. Lung cancer. New Engl J Med. 2008;359:1367\u201380.","journal-title":"New Engl J Med"},{"key":"110_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11523-016-0465-2","volume":"11","author":"GM Keating","year":"2016","unstructured":"Keating GM. Afatinib: a review in advanced non-small cell lung cancer. Target Oncol. 2016;11:825\u201335.","journal-title":"Target Oncol"},{"key":"110_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","volume":"11","author":"M Schuler","year":"2016","unstructured":"Schuler M, Wu YL, Hirsh V, O\u2019Byrne K, Yamamoto N, Mok T, et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11:380\u201390.","journal-title":"J Thorac Oncol"},{"key":"110_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, Tan EH, O\u2019Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577\u201389.","journal-title":"Lancet Oncol"},{"key":"110_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","volume":"16","author":"JC Yang","year":"2015","unstructured":"Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141\u201351.","journal-title":"Lancet Oncol"},{"key":"110_CR8","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1158\/0008-5472.CAN-14-3167","volume":"75","author":"CA Eberlein","year":"2015","unstructured":"Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 2015;75:2489\u2013500.","journal-title":"Cancer Res"},{"key":"110_CR9","doi-asserted-by":"crossref","unstructured":"Torigoe H, Shien K, Takeda T, Yoshioka T, Namba K, Sato H, et al. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations. Cancer Sci. 2018;109:1493\u2013502.","DOI":"10.1111\/cas.13571"},{"key":"110_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69\u201380.","journal-title":"Cell"},{"key":"110_CR11","doi-asserted-by":"publisher","first-page":"8961","DOI":"10.1158\/0008-5472.CAN-05-1187","volume":"65","author":"JM Teodoridis","year":"2005","unstructured":"Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 2005;65:8961\u20137.","journal-title":"Cancer Res"},{"key":"110_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-337","volume":"9","author":"W Dai","year":"2008","unstructured":"Dai W, Teodoridis JM, Graham J, Zeller C, Huang TH, Yan P, et al. Methylation linear discriminant analysis (MLDA) for identifying differentially methylated CpG islands. BMC Bioinformatics. 2008;9:337.","journal-title":"BMC Bioinformatics"},{"key":"110_CR13","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1158\/0008-5472.CAN-09-3427","volume":"70","author":"X Chang","year":"2010","unstructured":"Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, et al. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res. 2010;70:2870\u20139.","journal-title":"Cancer Res"},{"key":"110_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/cr.2014.3","volume":"24","author":"XL Ping","year":"2014","unstructured":"Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang WJ, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24:177\u201389.","journal-title":"Cell Res"},{"key":"110_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nature11112","volume":"485","author":"D Dominissini","year":"2012","unstructured":"Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201\u20136.","journal-title":"Nature"},{"key":"110_CR16","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1101\/gad.269415.115","volume":"29","author":"S Ke","year":"2015","unstructured":"Ke S, Alemu EA, Mertens C, Gantman EC, Fak JJ, Mele A, et al. A majority of m6A residues are in the last exons, allowing the potential for 3\u2019 UTR regulation. Genes Dev. 2015;29:2037\u201353.","journal-title":"Genes Dev"},{"key":"110_CR17","doi-asserted-by":"crossref","unstructured":"Molinie B, Wang J, Lim KS, Hillebrand R, Lu Z-X, Wittenberghe NV, et al. m(6)A-LAIC-seq reveals the census and complexity of the m(6)A epitranscriptome. Nat Methods. 2016;13:692\u20138.","DOI":"10.1038\/nmeth.3898"},{"key":"110_CR18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.cell.2013.10.026","volume":"155","author":"JM Fustin","year":"2013","unstructured":"Fustin JM, Doi M, Yamaguchi Y, Hida H, Nishimura S, Yoshida M, et al. RNA-methylation-dependent RNA processing controls the speed of the circadian clock. Cell. 2013;155:793\u2013806.","journal-title":"Cell"},{"key":"110_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.molcel.2012.10.015","volume":"49","author":"G Zheng","year":"2013","unstructured":"Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49:18\u201329.","journal-title":"Mol Cell"},{"key":"110_CR20","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","volume":"161","author":"X Wang","year":"2015","unstructured":"Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, et al. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161:1388\u201399.","journal-title":"Cell"},{"key":"110_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.molcel.2016.03.021","volume":"62","author":"S Lin","year":"2016","unstructured":"Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62:335\u201345.","journal-title":"Mol Cell"},{"key":"110_CR22","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.cell.2015.10.012","volume":"163","author":"KD Meyer","year":"2015","unstructured":"Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA, Elemento O, et al. 5\u2019 UTR m(6)A Promotes cap-independent translation. Cell. 2015;163:999\u20131010.","journal-title":"Cell"},{"key":"110_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nature15377","volume":"526","author":"J Zhou","year":"2015","unstructured":"Zhou J, Wan J, Gao X, Zhang X, Jaffrey SR, Qian SB. Dynamic m(6)A mRNA methylation directs translational control of heat shock response. Nature. 2015;526:591\u20134.","journal-title":"Nature"},{"key":"110_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/ncb2902","volume":"16","author":"Y Wang","year":"2014","unstructured":"Wang Y, Li Y, Toth JI, Petroski MD, Zhang Z, Zhao JC. N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. Nat Cell Biol. 2014;16:191\u20138.","journal-title":"Nat Cell Biol"},{"key":"110_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10:93\u20135.","journal-title":"Nat Chem Biol"},{"key":"110_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505:117\u201320.","journal-title":"Nature"},{"key":"110_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.gpb.2012.12.002","volume":"11","author":"Y Niu","year":"2013","unstructured":"Niu Y, Zhao X, Wu YS, Li MM, Wang XJ, Yang YG. N6-methyl-adenosine (m6A) in RNA: an old modification with a novel epigenetic function. Genomics Proteomics Bioinformatics. 2013;11:8\u201317.","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"110_CR28","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955\u201361.","journal-title":"Nucleic Acids Res"},{"key":"110_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fonc.2014.00040","volume":"4","author":"M McDermott","year":"2014","unstructured":"McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, et al. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Front Oncol. 2014;4:40.","journal-title":"Front Oncol"},{"key":"110_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nature23883","volume":"549","author":"C Zhang","year":"2017","unstructured":"Zhang C, Chen Y, Sun B, Wang L, Yang Y, Ma D, et al. m(6)A modulates haematopoietic stem and progenitor cell specification. Nature. 2017;549:273\u20136.","journal-title":"Nature"},{"key":"110_CR31","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1101\/gad.262766.115","volume":"29","author":"Y Yue","year":"2015","unstructured":"Yue Y, Liu J, He C. RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation. Genes Dev. 2015;29:1343\u201355.","journal-title":"Genes Dev"},{"key":"110_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.stem.2014.09.019","volume":"15","author":"PJ Batista","year":"2014","unstructured":"Batista PJ, Molinie B, Wang J, Qu K, Zhang J, Li L, et al. m(6)A RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell. 2014;15:707\u201319.","journal-title":"Cell Stem Cell"},{"key":"110_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/cr.2018.7","volume":"28","author":"J Tong","year":"2018","unstructured":"Tong J, Cao G, Zhang T, Sefik E, Amezcua Vesely MC, Broughton JP, et al. m(6)A mRNA methylation sustains Treg suppressive functions. Cell Res. 2018;28:253\u20136.","journal-title":"Cell Res"},{"key":"110_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-5-78","volume":"5","author":"F Di Nicolantonio","year":"2005","unstructured":"Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, et al. Cancer cell adaptation to chemotherapy. BMC Cancer. 2005;5:78.","journal-title":"BMC Cancer"},{"key":"110_CR35","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1080\/15384101.2017.1388972","volume":"16","author":"J Wang","year":"2017","unstructured":"Wang J, Zhou F, Li Y, Li Q, Wu Z, Yu L, et al. Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition. Cell Cycle. 2017;16:2355\u201365.","journal-title":"Cell Cycle"},{"key":"110_CR36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/1479-7364-3-3-281","volume":"3","author":"V Vasiliou","year":"2009","unstructured":"Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 2009;3:281\u201390.","journal-title":"Hum Genomics"},{"key":"110_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2999-1","volume":"17","author":"IA Cree","year":"2017","unstructured":"Cree IA, Charlton P. Molecular chess? Hallmarks of anti-cancer drug resistance. BMC Cancer. 2017;17:10.","journal-title":"BMC Cancer"},{"key":"110_CR38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/JTO.0b013e318283dcc0","volume":"8","author":"S Kim","year":"2013","unstructured":"Kim S, Kim TM, Kim DW, Go H, Keam B, Lee SH, et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol. 2013;8:415\u201322.","journal-title":"J Thorac Oncol"},{"key":"110_CR39","doi-asserted-by":"publisher","first-page":"20132030","DOI":"10.1098\/rspb.2013.2030","volume":"280","author":"CC Murdock","year":"2013","unstructured":"Murdock CC, Moller-Jacobs LL, Thomas MB. Complex environmental drivers of immunity and resistance in malaria mosquitoes. Proc Biol Sci. 2013;280:20132030.","journal-title":"Proc Biol Sci"},{"key":"110_CR40","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijid.2015.01.014","volume":"32","author":"JD Fonseca","year":"2015","unstructured":"Fonseca JD, Knight GM, McHugh TD. The complex evolution of antibiotic resistance in Mycobacterium tuberculosis. Int J Infect Dis. 2015;32:94\u2013100.","journal-title":"Int J Infect Dis"},{"key":"110_CR41","doi-asserted-by":"crossref","unstructured":"Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barab\u00e1si A-L, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9:2691.","DOI":"10.1038\/s41467-018-05116-5"},{"key":"110_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09186-x","volume":"10","author":"F Cheng","year":"2019","unstructured":"Cheng F, Kovacs IA, Barabasi AL. Network-based prediction of drug combinations. Nat Commun. 2019;10:1197.","journal-title":"Nat Commun"},{"key":"110_CR43","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2174\/138161209787582156","volume":"15","author":"A Katsman","year":"2009","unstructured":"Katsman A, Umezawa K, Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des. 2009;15:792\u2013808.","journal-title":"Curr Pharm Des"},{"key":"110_CR44","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1054\/drup.1999.0097","volume":"2","author":"WS Dalton","year":"1999","unstructured":"Dalton WS. The tumor microenvironment as a determinant of drug response and resistance. Drug Resist Updat. 1999;2:285\u20138.","journal-title":"Drug Resist Updat"},{"key":"110_CR45","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","volume":"93","author":"JS Damiano","year":"1999","unstructured":"Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658\u201367.","journal-title":"Blood"},{"key":"110_CR46","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/9511","volume":"5","author":"T Sethi","year":"1999","unstructured":"Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med. 1999;5:662\u20138.","journal-title":"Nat Med"},{"key":"110_CR47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/tpj.2014.45","volume":"15","author":"Y Zheng","year":"2015","unstructured":"Zheng Y, Zhou J, Tong Y. Gene signatures of drug resistance predict patient survival in colorectal cancer. Pharmacogenomics J. 2015;15:135\u201343.","journal-title":"Pharmacogenomics J"},{"key":"110_CR48","doi-asserted-by":"crossref","first-page":"12598","DOI":"10.18632\/oncotarget.7181","volume":"7","author":"M Zhou","year":"2016","unstructured":"Zhou M, Wang X, Shi H, Cheng L, Wang Z, Zhao H, et al. Characterization of long non-coding RNA-associated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer. Oncotarget. 2016;7:12598\u2013611.","journal-title":"Oncotarget"},{"key":"110_CR49","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/CAD.0b013e3283330590","volume":"20","author":"H Modjtahedi","year":"2009","unstructured":"Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anti-Cancer Drugs. 2009;20:851\u20135.","journal-title":"Anti-Cancer Drugs"},{"key":"110_CR50","doi-asserted-by":"publisher","first-page":"224ra26","DOI":"10.1126\/scitranslmed.3007947","volume":"6","author":"S Misale","year":"2014","unstructured":"Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med. 2014;6:224ra26.","journal-title":"Sci Transl Med"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0110-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0110-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0110-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:00:04Z","timestamp":1684616404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-019-0110-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["110"],"URL":"https:\/\/doi.org\/10.1038\/s41397-019-0110-4","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"2 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}